In 28,612 men from the Cooper Center Longitudinal Study linked to Medicare claims, higher treadmill-measured cardiorespiratory fitness predicted lower incidence of colorectal cancer (HR 0.91 per MET) and lung cancer (HR 0.81 per MET), but not prostate cancer. Among 4,998 men diagnosed with these cancers, high-fit men had a 33-41% lower likelihood of all-cause death, with generally lower cardiovascular and other non-cancer mortality as well.
The prostate null and the survival pattern are the most informative parts. Fitness protects against cancers with strong links to inflammation, insulin signaling, obesity and smoking, while prostate cancer shows little relationship, which echoes earlier physical activity literature. The survival benefit leans heavily on non-cancer deaths: fit patients tolerate treatment better and die less often from heart disease, so fitness works partly as a marker of physiological reserve rather than a direct anticancer effect. The lung cancer estimate deserves caution. Smoking drives both low fitness and lung cancer, and residual confounding is likely even with adjustment. The cohort is also predominantly white, affluent, well-educated men with access to preventive care, and Medicare linkage captures only those aged 65 and older, so generalizability to women and diverse populations is limited. Observational data cannot prove that raising fitness lowers risk. Still, the per-MET gradient gives a usable target, since one MET is roughly the gain many sedentary adults achieve with several months of regular aerobic training. This confirms and sharpens existing evidence rather than overturning it, and it strengthens the case for treating fitness as a vital sign in cancer prevention.